BRTX צמיחת הכנסות מרבעון לרבעון BioRestorative

Quarterly revenue growth rates reflect current dynamics, with the value standing at -7.30. BioRestorative Therapies (BRTX) relies on ThermoCell to combat obesity and back pain. The company drives development through university partnerships and patent acquisitions; however, BioRestorative Therapies (BRTX) faces a capital shortage and a lack of sales due to clinical trial expenses.
פילוחים אנליטיים של חברת BioRestorative (BRTX)

This indicator measures the percentage dynamics of quarterly commercial revenues relative to the preceding period, allowing for an assessment of business scaling rates through daily calculations. The trend analysis of quarterly revenue changes confirms the financial instability of BioRestorative Therapies (BRTX), as the lack of market pricing power and the current FDA clinical trial stage render this metric effectively zero.